What Relactagel Treats: Main Uses and Benefits

Relactagel is commonly used for the symptomatic management of Bacterial Vaginosis (BV), a condition where symptoms may intensify temporarily. Non-antimicrobial gels are relevant in clinical settings that involve acute or unstable symptom patterns.

The primary therapeutic use is applied across domains where additional symptomatic support is needed, contributing to functional stability. The product is applied in addressing situations involving recurrent or episodic manifestations. It is relevant for easing symptom clusters, which may include the unpleasant, fishy odour and abnormal discharge. It is considered relevant for use by pregnant patients seeking management for BV symptoms and for use following physiological triggers like menstruation. This supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Unpleasant Odour The product is commonly used when short-term symptomatic assistance is needed, offering support that helps ease the overall symptom burden, which includes the management of offensive odour.

Who can and cannot use Relactagel?

Relactagel is intended for use by adult females, and its eligibility is determined by local factors and ingredient sensitivity, consistent with its status as a medical device. The official labeling outlines specific contraindications and conditional restrictions on use.

---

Populations for whom use is contraindicated

Use is absolutely prohibited for individuals with a known hypersensitivity or allergy to any component. This includes specific ingredient-based contraindications:

• Allergy to the specific glycogen source in the formulation (e.g., maize or shellfish/oysters).

---

Age-related eligibility and special states

Population Group	Eligibility Status (Regulatory Basis)
Adult Females	Permitted (Target population, generally 16 years).
Pediatric Use	Not for use in children.
Pregnancy	Permitted and safe to use for managing BV symptoms.

---

Eligibility-related restrictions

Use is conditional or restricted in the following contexts:

• Trying to Conceive (TTC): Use should be avoided when attempting conception, as the gel’s acidity may impair semen function.
• Local Conditions: Use may cause mild irritation if applied when vaginal tears or an active fungal infection (thrush) are present.

No restrictions are documented concerning systemic organ function, such as hepatic or renal impairment.

The official interaction profile for Relactagel is primarily defined by its local, non-systemic administration and its classification as a medical device in several jurisdictions. Consequently, no systemic drug-drug interactions, such as those involving metabolic enzymes or drug transporters, are documented in government regulatory labeling.

Absence of Systemic Interactions

Interaction Type	Official Regulatory Statement
Systemic Drug-Drug	No systemic pharmacokinetic interactions (e.g., CYP-mediated effects, exposure modification) are officially documented with oral medications.
Ingested Substances	No interactions with food, alcohol, or herbal products are specified in regulatory guidance due to the product's local route.

Local Co-administration Restrictions

The only official interaction constraints relate to the local administration site, which are defined as pharmacodynamic (efficacy-based) restrictions:

• Interacting Product Category: Locally-applied intravaginal products, including other gels, suppositories, or vaginal spermicides, are known to interact with the physical and chemical action of Relactagel.
• Required Restriction: Co-administration with other intravaginal treatments is advised against to prevent physical interference or potential loss of the intended local effect, as described in product instructions for use.

The regulatory structure confirms that the product's function as a pH regulator imposes constraints only on the concurrent use of other agents in the local environment, ensuring its core function is maintained.

Mechanism of Action: Lactate and Glycogen Delivery

Relactagel operates through a dual-mechanism focused on modulating the local vaginal environment. The formulation delivers lactate ions directly into the vaginal lumen. These ions function as a physicochemical modifier, contributing to the maintenance of the vaginal pH within the acidic range of 3.5-4.5. This pH modulation creates an environmental condition that selectively favors the proliferation and metabolic activity of endogenous Lactobacillus species.

Concurrently, the gel provides a high concentration of glycogen. This glycogen is introduced to serve as an external nutrient substrate for the Lactobacillus bacteria. By supplementing the primary energy source of these organisms, the mechanism supports their sustained growth and colonization. The physiological consequence of this dual-action mechanism is the modulation of the microbial balance through targeted physicochemical and nutritional support, remaining strictly within the biochemical and ecological domain without reference to clinical outcomes.

Instruction Map: How to Use Relactagel — Standardized Administration Guidelines

This map summarizes the standardized administration principles for Relactagel, as documented in patient and clinical guidelines.

Feature	Detail
Route of administration:	Intravaginal
Dosing schedule (Treatment):	One single-use 5 mL application daily for 7 days.
Dosing schedule (Maintenance):	One single-use 5 mL application daily for 2 to 3 days after menstruation.
Timing in relation to meals:	Not applicable (topical route).
Age-group administration rules:	Permitted for use during pregnancy for appropriate conditions.
Special procedural conditions:	Application must be performed at bedtime when the user is lying down to minimize potential leakage.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type:	Topical (vaginal gel)
Frequency pattern:	Daily, either as a continuous 7-day course or an intermittent 2- to 3-day cycle.
Use-context constraints:	The product is a single-use dose, and it should be avoided by individuals actively trying to conceive, as its functional action may interfere with conception.

Resulting Procedural Structure

Step sequence:

• Use the contents of one single-use pre-filled 5 mL applicator.
• The product must be administered once daily at bedtime.
• The applicator is for single use only and must be discarded immediately after administration.

Connection to the overall use protocol (2–4 sentences): Standard administration protocols establish two use patterns: a continuous 7-day treatment course for acute use, and a shorter 2- to 3-day intermittent course for maintenance. These protocols dictate the standardized 5 mL dose and the required bedtime timing, defining the complete procedure for proper administration.

Research evidence / Overview of Studies for Relactagel

This section provides a summary of the types of research that have been conducted on Lactic Acid and Glycogen gels, like Relactagel, focusing only on the structure of the evidence and what studies have observed, without providing clinical advice or treatment recommendations.

---

Evidence for Symptomatic Bacterial Vaginosis (BV)

Research has explored Lactic Acid/Glycogen gels in studies focusing on symptomatic Bacterial Vaginosis. The evidence base includes Randomized Controlled Trials (RCTs) and Systematic Reviews, which are used in research exploring how symptoms change over time compared to other approaches. The outcomes related to physical discomfort that were measured included whether participants reported a resolution of symptoms like unpleasant odor and discharge. Studies also monitored changes in the vagina's pH and microbiological status.

What remains uncertain is the overall strength of this evidence. Systematic reviews often note that the evidence quality varies across studies, with some having design limitations. Research highlights that the findings were mixed when assessing microbiological resolution outcomes compared to oral antibiotic treatments. Furthermore, long-term effects are not fully established, particularly when examining recurrence patterns over many months.

---

Evidence on Environmental Restoration and Biomarkers

Beyond symptomatic use, studies have explored how Lactic Acid/Glycogen gels affect the vaginal environment itself. This research examined temporary physiological imbalance by focusing on objective biomarkers, such as monitoring the measurement of vaginal pH change from an elevated level. These studies observed outcomes related to systemic or functional imbalance in women who showed signs of non-optimal flora. These findings describe patterns observed in the studies related to the measured pH and other biomarkers following use.

Limited information for long-term outcomes is available when the research only focuses on these biomarkers. The evidence contributes to understanding the short-term changes but does not fully establish the clinical significance of these immediate shifts over extended periods.

---

What Research Shows is Still Uncertain

Research highlights that findings were mixed when assessing microbiological resolution outcomes compared to standard antibiotic treatments for BV. Additionally, long-term effects are not fully established, as follow-up durations were limited in many studies focusing on recurrence prevention. Overall, this research contributes to the broader evidence landscape, but it highlights what is known — and what is still uncertain — about the full scope of the gel's use.

Common questions about Relactagel (FAQ)

Q: What specific conditions is Relactagel typically used to manage?

Regulatory information states that Relactagel is typically used for the treatment and prevention of Bacterial Vaginosis (BV). It is also used to relieve the symptoms associated with BV, such as abnormal discharge and unpleasant odour.

Q: Does Relactagel help address the root cause of symptoms?

Official descriptions indicate the product works by addressing the microbial imbalance itself. It functions by restoring the natural acidic pH and providing glycogen as a nutrient to encourage the growth of the vagina's natural protective bacteria (lactobacilli).

Q: Is Relactagel generally considered suitable for long-term use?

The official product guidance includes a specific maintenance schedule designed for prevention, which is used for 2-3 days after menstruation. The existence of this maintenance schedule is noted in the guidance for repeated, intermittent use to support a healthy vaginal environment.

Q: How quickly does Relactagel typically begin to show a noticeable effect?

Official information states that the product is designed to rapidly restore the vaginal pH to its natural acidic level. In studies, patient reports have noted an immediate local soothing effect, which is linked to this rapid pH correction.

Q: Is the effect of Relactagel intended to be immediate?

The mechanism of action is designed for the lactic acid to rapidly lower the elevated pH. This immediate environmental change is intended to begin relieving associated symptoms like abnormal discharge and odour.

Q: What is the difference between Relactagel and common bacterial vaginosis treatments?

According to regulatory classifications, Relactagel is a Class IIa medical device and functions as a non-antibiotic treatment by regulating the vaginal pH. Common prescription treatments for BV are generally antibiotics, which work differently by killing bacteria directly.

Q: Can Relactagel be used during a menstrual period?

The official use protocols specify that the recommended maintenance course of application should be used after menstruation has finished. This protocol does not include use during the menstrual period itself.

Q: Can Relactagel be used by individuals who are not women?

Regulatory information and official claims focus exclusively on its use for adult females for the treatment and prevention of Bacterial Vaginosis (BV). BV is a condition specific to the vaginal environment.

Q: Does Relactagel contain any hormones or preservatives?

Official product information confirms that Relactagel contains no preservatives. The core functional ingredients are lactic acid and glycogen, and no hormones are listed as part of the formulation.

Q: What is the difference between Relactagel and a general personal lubricant?

Relactagel is classified as a medical device and its purpose is to treat and prevent BV by regulating the vaginal pH balance. A general personal lubricant, in contrast, is primarily intended to reduce friction for comfort during sexual activity.

How to Store and Dispose of Relactagel

Relactagel Vaginal Gel must be stored according to the requirements specified on the product label to ensure its stability.

Storage Conditions

Storage Requirement	Specification
Temperature	Do not store above 25ºC.
Protection	Keep out of direct sunlight and in a cool, dry place.
Safety	Keep the product out of the reach and sight of children.
Stability	Do not use beyond the expiry date. Use the contents of an opened tube immediately.

Disposal Instructions

Each applicator tube is for single use only and must not be reused. The used or expired tube must be discarded appropriately in a waste bin. It is explicitly instructed not to dispose of the tube by flushing it down the toilet or into wastewater.